Aim: Myostatin (Mstn) has been described as a trigger for the progression of atherosclerosis. In this study, we evaluated the role of Mstn in arterial remodeling in patients with end-stage renal disease (ESRD).

Methods: Vascular specimens were collected from 16 ESRD patients (56.4 ± 7.9 years) undergoing renal transplant (recipients) and 15 deceased kidney non-uremic donors (55.4 ± 12.1 years). We studied gene and protein expression of Mstn, ubiquitin ligases, Atrogin-1, and muscle ring finger protein-1 (MuRF-1), inflammatory marker CCL2, cytoskeleton components, and Klotho by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Moreover, we assessed vascular calcification and collagen deposition. Finally, we studied the effects of recombinant Mstn on rat vascular smooth muscle cells (VSMCs, A7r5) and evaluated the effects of uremic serum (US) on primary human VSMCs.

Results: Myostatin mRNA was upregulated in the arterial vascular wall of recipients compared with donors (~15-fold, \( p < 0.05 \)). This response was accompanied by the upregulation of gene expression of Atrogin-1 and MuRF-1 (\( \times 2.5 \) - and \( \times 10 \)-fold) and CCL2 (\( \times 3 \)-fold). Conversely, we found downregulation of protein expression of Smoothelin, \( \alpha \)-smooth muscle actin (\( \alpha \)-SMA), vimentin, and Klotho (-85%, -50%, -70%, and -80%, respectively; \( p < 0.05 \)) and gene expression of vimentin and Klotho. Exposition of A7r5 to Mstn induced a time-dependent SMAD 2/SMAD 3 phosphorylation and expression of collagen-1 and transforming growth factor \( \beta \) (TGF\( \beta \)) mRNA, while US induced overexpression of Mstn and Atrogin-1 and downregulation of Smoothelin and Klotho.

Conclusions: Our data suggest that uremia might induce vascular Mstn gene expression together with a complex pathway of molecular and structural changes in the vascular wall. Myostatin, in turn, can translate the metabolic alterations of uremia into profibrotic and stiffness inducing signals.

Key words: Myostatin, Uremic vasculopathy, Vascular fibrosis, Klotho, Vascular smooth muscle cells

Introduction

Cardiovascular disease accounts for more than 50% of total chronic kidney disease (CKD) mortality and is the most prevalent complication observed in CKD patients, especially in those affected by end-stage renal disease (ESRD) requiring dialysis\(^1\). Uremic vascular disease presents unique features, including accelerated aging, abnormal resistance vessel remodel-
reduced expression of VSMC marker proteins, such as α-smooth muscle actin (α-SMA), smooth muscle 22-alpha (TAGLN), smooth muscle myosin heavy chain (MYH11), the transcription factor myocardin, and Smoothelin. These changes result in increased proliferative and migratory rate of VSMCs and release of a number of chemo- and cytokines that, interacting with infiltrating cells, boost inflammation and cause loss of arterial elasticity and deterioration of the vessel wall. This condition might be further aggravated in uremia, where VSMCs acquire a calcifying phenotype, characterized by the upregulation of osteochondro-cytic genes, finally leading to vascular calcification. It is commonly retained that this process is regulated by the combination of several factors, such as hyperphosphatemia, inflammation, Klotho deficiency, reduced levels of calcification inhibitors, and expression of pro-fibrotic molecules.

Myostatin (Mstn), a 375-amino acid peptide member of the transforming growth factor β (TGFβ) superfamily, is primarily expressed in skeletal muscle cells, where it limits muscle growth and promotes protein breakdown. Myostatin exerts its effects in both autocrine and paracrine ways by binding a cell-bound receptor activin type 2B. The complex Mstn receptor assembles with either the type I receptor ALK4 or ALK5 leading to the activation of intracellular signaling pathways including SMAD 2/SMAD 3 and Akt, which finally upregulate ubiquitin-proteasome system (UPS), causing protein degradation and muscle atrophy. Recent evidence indicates that, besides its effects on skeletal muscle atrophy, Mstn is involved in the pathogenesis of heart failure and fibrosis. Myostatin attenuates cardiomyocyte proliferation in models of cardiac hypertrophy and promotes myocardial fibrosis by blocking myofibroblast differentiation. Very recently, we observed that Mstn is upregulated in VSMC and in infiltrating macrophages of the abdominal aorta and that its expression progressively increases along with the severity of atherosclerotic damage. In additional experiments, we observed that Mstn downregulates cell proliferation and stiffness-related genes in rat VSMCs and acts as a chemoattractant in monocytes, raising the MCP-1-dependent chemotaxis. Overall, these studies indicate that Mstn actively participates in the progression of atherosclerotic damage. In CKD patients, Mstn is upregulated by inflammation in the skeletal muscle and plays a major role in uremic wasting and muscle fibrosis. Moreover, recent observations indicate that vessel activin receptor is upregulated in CKD. However, no information is available on the presence and localization of Mstn in the arterial wall of uremic patients and about its potential relationship with the different vascular regulatory pathways.

Materials And Methods

Patients and Vascular Samples

Vascular specimens were obtained from consecutive uremic patients with ESRD undergoing renal transplant (i.e., recipients) and paired deceased kidney non-uremic donors (considered as control group) at the time of surgery at “San Matteo” Hospital of Pavia, Italy. We enrolled patients aged 18–70 years, at their first transplant, with a dialysis vintage of at least 12 months. We collected demographic and clinical data, such as presence of comorbidities, and measured albumin, calcium, phosphorus, PTH, C-reactive protein (CRP), lipids, and lymphocyte count, while for recipients we also collected data on dialytic history. Informed written consent was obtained from all patients, and the study was approved by the local ethics committee.

Tissue mRNA Expression

Total RNA was extracted from vascular tissues using the guanidine-based RNeasy Mini Kit (QIA-GEN GmbH, Hilden, Germany). A total of 1 μg of RNA per condition was reversely transcribed by iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Segrate, Italy). The primers were obtained from TIB Molbiol (Genoa, Italy). The sequences are reported in Table 1. PCR amplification was carried out in a total volume of 10 μL, containing 1 μL cDNA solution, 5 μL SYBR solution PrecisionPLUS qPCR MasterMix (Primerdesign, Southampton, Great Britain), 0.5 μL each primer, and 3.5 μL of nuclelease-free water. β-actin was used for the normalization of expression values of the other genes. The ΔΔCT method of relative quantification was used to determine the fold change in expression. Assays were run in triplicate by a Universal PCR Master Mix on MasterCycler rea-plex (Eppendorf, Hamburg, Germany) PCR system.

Histological Preparation and Immunohistochemical Staining

Paraffin sections (5 μm) of 2% paraformaldehyde-fixed tissue were deparaffinized, hydrated, and treated with 3% H2O2 in methanol. Each sample was analyzed for the detection of Mstn (polyclonal antibody; Proteintech, DBA Italia s.r.l., Segrate, Italy), CCL2/MCP-1 (polyclonal antibody; Novus Biologica-1, monoclonal antibody; ECM Biosciences, DBA Italia s.r.l., Segrate, Italy), Klotho (polyclonal antibody; Abcam, Prodotti Gianni, Milan, Italy), Smoothelin, vimentin (monoclonal antibodies; Santa Cruz Biotechnology,
aprotinin, leupeptin, pepstatin A, 1 mM PMSF, and Na3VO4). Protein concentration was determined using the Bicinchoninic Protein Assay Kit (Merck Group, Vimodrone, Italy), and 10–20 µg of protein concentration were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred to a PVDF membrane (Merck Group, Vimodrone, Italy). Blots were probed using anti-phospho-SMAD 2, anti-phospho-SMAD 3, and SMAD 2/SMAD 3 polyclonal antibody (Cell Signaling Technology, EuroClone, Pero, Italy) and incubated in horseradish peroxidase secondary antibodies (Cell Signaling Technology, EuroClone, Pero, Italy). Immunoblots were developed with Immobilon Western Chemiluminescent HRP Substrate (Merck Group, Vimodrone, Italy). Band intensities were determined using Alliance system (Uvitec, Cambridge, UK).

cDNA Reverse Transcription and Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Total RNA was extracted by A7r5 cells using QIAzol Lysis Reagent (QIAGEN Italia, Milan, Italy) according to the manufacturer’s instructions. Total RNA (1 µg) was reverse transcribed into cDNA by iScript<sup>™</sup> RT Supermix (Bio-Rad Laboratories, Segrate, Italy). The gene expression of collagen-1 was quantified by real-time PCR as above described. The corresponding primers are reported in Table 1.

Primary Human VSMC Cultures

Aortic tissue was explanted by donors, cleaned of fatty tissue, and separated from intima and adventitia layers, leaving the tunica media alone. Subsequently, the tunica media was cut into 1–2 mm cubes, digested by collagenase and elastase (Sigma Aldrich, Milan, Italy), and transferred to 100 mm culture plates. After
Results

Patient Characteristics

At the time of kidney transplant, iliac artery patches were collected from 16 recipients (56.4 ± 7.9 years, nine males, dialysis vintage 68.7 ± 40.3 months) (Table 2). Fourteen patients were hypertensive, two patients were diabetic, and two were active smokers. Main underlying nephropathies included glomerulonephritis, nephroangiosclerosis, and adult dominant polycystic disease. As a control group, we considered aortic artery samples collected from 15 (55.4 ± 12.1 years, eight males) deceased kidney donors. Causes of deaths were as follows: intracerebral hemorrhage (eight patients), stroke (three patients), trauma (three patients), and brain tumor (one patient). Five subjects were hypertensive and four were active smokers. Their mean serum creatinine at time of the donation was 0.7 ± 0.23 mg/dl. Donors presented lower albumin levels than recipients (2.8 ± 0.7 vs. 3.7 ± 0.4 g/dl, p < 0.05), while there were not significant differences in age and sex distribution.

Table 2. Clinical and biochemical characteristics of patients at the enrollment

|                    | Recipients (ESRD pts) | Donors               |
|--------------------|-----------------------|----------------------|
| N                  | 16                    | 15                   |
| Age (years)        | 56.4 ± 7.9            | 55.4 ± 12.1          |
| Sex, male/female   | 9/7                   | 8/7                  |
| BMI (kg/m²)        | 24.2 ± 2.9            | 26.9 ± 4             |
| Hypertension, n (%)| 14 (87.5%)*           | 5 (33%)              |
| Diabetes, n (%)    | 2 (12.5%)*            | 0                    |
| Active smokers, n (%)| 2 (12.5%)             | 4 (26%)              |
| Dialysis vintage (months) | 68.7 ± 40.3 | -                    |
| Serum albumin (g/dl)| 3.7 ± 0.4*            | 2.8 ± 0.7            |
| CRP (mg/dl)        | 0.36 ± 0.6            | 0.9 ± 0.6            |
| Phosphate (mg/dl)  | 4.3 ± 1.3             | 3.7 ± 2.3            |
| Corrected calcium (mg/dl) | 9.5 ± 0.9         | 9.7 ± 0.8            |
| PTH (pg/ml)        | 405 (149-543)         | -                    |

Abbreviations: ESRD = End-stage renal disease, BMI = Body mass index, CRP = C-Reactive Protein, HD = Hemodialysis, PD = Peritoneal Dialysis, * = p < 0.05 vs donors.

Statistical Analysis

Quantitative variables were represented by mean ± standard deviation (SD) or median-interquartile ranges (IQR) if they were not normally distributed (Shapiro test). Differences among groups were assessed by Student t-test or nonparametric Mann-Whitney test when appropriated. Correlations were analyzed using Spearman-Rho rank test. All tests were two-sided, and p < 0.05 was considered statistically significant. Data analysis was performed with GraphPad Prism statistical package (version 5.00, GraphPad Software, San Diego, California, USA).

Arterial Mstn Expression and Localization in Uremic Patients

There was a greater than 15-fold increase in Mstn mRNA levels in the vascular wall of recipients compared to donors (p < 0.05) (Fig. 1A). The Mstn immunohistochemical signal in recipients was not different from donors (Fig. 1B).

The immunohistochemical signal showed that Mstn was mainly localized in the tunica media, in infiltrating cells, and neovasa both in recipients and
Vascular Cytoskeleton Protein Expression is Downregulated in Uremic Patients

In arterial samples of recipients, VSMCs showed an altered morphology, characterized by loss of their elongated and spindle shape and appearance of a rounded phenotype (Fig. 3A). Coherently, we found that protein expression of cytoskeleton components, such as Smoothelin and α-SMA, was blunted or significantly decreased (by 50%–85% vs. donors, \(p \leq 0.001–0.05\), respectively), while no significant differences were observed in their mRNAs (Fig. 3B, C). On the opposite, both vimentin mRNA and its protein were downregulated (by 40%–70%, \(p < 0.05\)) (Fig. 3D).

Myostatin Localization in Arterial Resident VSMCs and Bloodstream-Derived Cells

To gain information on the cell types responsible for Mstn enrichment within the vessel wall, we performed colocalization studies of Mstn with α-SMA and CD45, markers of VSMCs, and cells from hematopoietic lineage, respectively. Myostatin staining colocalized with α-SMA in VSMC (Fig. 2A) and with infiltrating CD45+ cells (Fig. 2C). Interestingly, some CD45+/Mstn+ cells were also positive for α-SMA (Fig. 2B, C), marker of fibrosis, leading to hypothesize the commitment of bloodstream-derived cells toward a fibroblast-like differentiation within the vessel wall. The colocalization was assessed only in donor specimens.

Finally, vascular protein and gene expression of Mstn did not significantly correlate with any basal clinical and laboratory characteristics of both recipients and donors.

**Fig. 1.**

Expression of Mstn mRNA (A) and protein (B) in human aorta of donors (\(N=16\)) and the iliac artery of recipients (\(N=13\)). Myostatin mRNA expression level was determined by real-time PCR. Myostatin protein expression was evaluated by immunohistochemistry and image analysis. (C) Representative pictures of immunohistochemistry staining in donor and recipient arteries. Myostatin positivity was detectable in the tunica media, infiltrating cells (INF), and neovasa (NV) (magnification: x 100–1000). Data are expressed as fold change ± SEM to donor aortas. \(*p < 0.05\) vs. donors.

Vascular Cytoskeleton Protein Expression is Downregulated in Uremic Patients

In arterial samples of recipients, VSMCs showed an altered morphology, characterized by loss of their elongated and spindle shape and appearance of a rounded phenotype (Fig. 3A). Coherently, we found that protein expression of cytoskeleton components, such as Smoothelin and α-SMA, was blunted or significantly decreased (by 50%–85% vs. donors, \(p < 0.001–0.05\), respectively), while no significant differences were observed in their mRNAs (Fig. 3B, C). On the opposite, both vimentin mRNA and its protein were downregulated (by 40%–70%, \(p < 0.05\)) (Fig. 3D).

Atrogin-1 and MuRF-1 are Upregulated in the Vascular Wall of Uremic Patients

Consistent with the previous evidence that showing in skeletal muscle an upregulation of atrophic signaling elements of the UPS, we observed that Atrogin-1 and muscle ring finger protein-1 (MuRF-1) mRNAs significantly increased (2.5-fold Atrogin-1
and 10-fold MuRF-1, $p<0.05$) (Fig. 3E). In addition, Atrogin-1 protein levels also rose up (+2.6-fold).

**CCL2/MCP-1 is Expressed in Arterial Wall of Donors and Recipients**

Previously, we have shown that Mstn induces pro-inflammatory changes in VSMC cell line by increasing CCL2, and it has been demonstrated that a chronic inflammation could be a possible trigger of vascular damage. Then, we evaluated the expression of CCL2 in the vascular wall of recipients compared to donors. Interestingly, as depicted in Fig. 4A–B, we found out that CCL2 gene expression had the same trend as Mstn; indeed, CCL2 mRNA was overexpressed in recipients (threefold in donors, $p<0.05$), while protein expression has no difference.

**Calcification, Klotho Expression, and Collagen Accumulation**

Both recipients and donors showed extensive positive calcification areas in the tunica media (Fig. 5A). Klotho mRNA was detectable in donor arteries (Fig. 5B), while in recipients Klotho mRNA was markedly downregulated (-88%, $p<0.001$). Klotho protein expression was present in 5/15 donors (33%) and was very weakly expressed in only 1/16 recipients (6%) (Fig. 5B). Collagen-1 gene expression was similar in recipients and donors; in addition, by Picrosirius red staining, no differences in collagen deposition were observed (Fig. 6A, B).

**Myostatin Has Profibrotic Effects on A7r5 VSMC**

Exposure of A7r5 rat VSMCs to Mstn induced a time-dependent increase of collagen-1 mRNA (by 12- to 7-folds vs. untreated cells, $p<0.05$) (Fig. 7A). Myostatin also induced TGF-β mRNA expression (Fig. 7B). Lastly, Mstn activated SMAD 2/SMAD 3 by phosphorylation, an effect that was observed after 45 minutes (+55%–60% vs. T0, $p<0.01$) and persisted during the whole time course (Fig. 7C).

**Effect of US on Human VSMC**

To explore the effects of potential uremic toxins retained in blood in uremia, human VSMCs were treated with 10% US for 24 hours. US induced a 60%–70% ($p<0.05$–0.01, respectively), increase in Mstn and Atrogin-1 mRNAs (Fig. 8A, B). Also, US exposure downregulated Smoothenin expression (-30%, $p<0.05$) (Fig. 8C) and heavily blunted Klotho mRNA at 24 hours ($p<0.05$) and 48 hours ($p<0.01$) (Fig. 8D).
Fig. 3.
(A) Tissues were stained by hematoxylin and eosin staining. In recipient arteries, arrows indicate VSMC that lost elongated and spindle shape and showed a rounded phenotype (magnification: x 100). (B) Expression of Smoothelin mRNA and protein in human aorta of donors (N=16) and the iliac artery of recipients (N=13). Smoothelin mRNA expression level was determined by real-time PCR. Photos are representative of Smoothelin distribution in donor and recipient vasa. (C) Expression of α-SMA mRNA and protein in human aorta of donors and the iliac artery of recipients. Note that recipient vasa are very scarcely positive for α-SMA. (D) Expression of vimentin mRNA and protein. Both were significantly downregulated in recipient arteries. Pictures show a strong positivity in donor VSMC and a faintly immunostaining in recipients. (E) Atrogin-1 and MuRF-1 expression. mRNA levels were evaluated by real-time PCR and protein expression by immunohistochemistry and image analysis (magnification: x 100–400). Data are expressed as fold change ± SEM to donor aortas. *p<0.05, **p<0.001 vs. donors.

Fig. 4.
(A) Expression of CCL2 mRNA and protein in human aorta of donors (N=16) and the iliac artery of recipients (N=13). CCL2 mRNA expression level was determined by real-time PCR. CCL2 protein expression was evaluated by immunohistochemistry and image analysis. (B) Representative pictures of immunohistochemistry staining in donor and recipient arteries (magnification: x 200–400). Data are expressed as fold change ± SEM to donor aortas. *p<0.05 vs. donors.
Fig. 5.
(A) Von Kossa staining on donor and recipient vasa. Positive areas, which appeared as thin granules or coarse deposits with focal or diffuse distribution, were evaluated by image analysis. Note that there are no differences in intensity staining. (B) Expression of Klotho mRNA and protein in human aorta of donors (N=16) and the iliac artery of recipients (N=13). Klotho mRNA and protein were strongly downregulated in recipients. Pictures show Klotho staining in donor media as also highlighted in box. mRNA level was evaluated by real-time PCR and protein expression by immunohistochemistry and image analysis (magnification: x 100–1000). Data are expressed as fold change ± SEM to donor aortas. *p < 0.01, **p < 0.001 vs. donors.

Fig. 6.
(A) Expression of collagen-1 mRNA in human aorta of donors (N=16) and the iliac artery of recipients (N=13). No differences were observed between recipient and donor tissues as indicated by Picosirius red staining (B). Slides were examined through a polarizing microscope. The larger collagen fibers were bright yellow or orange. Positivity was assessed by image analysis. Data are expressed as fold change ± SEM to donor aortas *p < 0.001 (magnification: x 100).
**Fig. 7.**
Effects of Mstn on A7r5 VSMC mRNA levels for collagen-1 (A) and TGF-β (B) were analyzed by real-time RT-PCR after 5- and 24-hour treatment. All data were firstly normalized to GAPDH mRNA, and gene expression was calculated relative to corresponding levels in no treated cells. (C) Effects of Mstn on SMAD 2/SMAD 3 phosphorylation. Cells were exposed to Mstn for 15, 45, 60 minutes, and cell lysates were analyzed by Western blot. Membranes were stripped and reprobed for non-phosphorylated SMAD. All results represent mean±SEM obtained from three independent experiments. *p<0.05, **p<0.01, ***p<0.001 vs. no treated cells.

**Fig. 8.**
The effect of NS and US on Mstn (A), Atrogin-1 (B), Smoothelin (C), and Klotho (D) mRNAs. Cells were incubated with 10% serum for 24–48 hours. mRNA expression was determined by real-time PCR. All results represent mean±SEM obtained from three independent experiments. *p<0.05, **p<0.01, vs. NS treated cells.
Discussion

Myostatin is upregulated by inflammation in skeletal muscle of patients with CKD and is a major contributor to the increase in protein degradation and muscle atrophy in this condition. However, if and to what extent Mstn is upregulated in uremic vascular tissue and what could be its role in promoting vascular fibrosis in uremia are still unknown.

Therefore, we focused our study on these topics, allowing us to make three major observations.

First, we identified in the vascular wall of ESRD patients an overexpression of Mstn mRNA, accompanied by the upregulation of Atrogin-1 and MuRF-1 members of E3 ligases and major effectors of protein degradation; increased expression of CCL2/MCP-1, described as a mediator of vascular inflammation; and decreased expression of cytoskeleton proteins and Klotho. As a second new finding, we observed that Mstn induced SMAD 2/SMAD 3 phosphorylation and upregulated TGFβ and collagen-1 mRNA in cultured VSMCs, indicating that Mstn has profibrotic effects in VSMCs. Finally, we observed that many of the changes observed in the uremic arterial wall were reproduced by US in human VSMCs.

These data suggest that uremia might induce a complex pathway of molecular and structural changes in vascular wall, including upregulation of protein degradation and inflammation, while Mstn might have a role in uremic-related vascular remodeling.

As first step, we investigated the expression of Mstn in the uremic vessels, finding that, such as in atherosclerosis (an inflammatory setting), also in ESRD, Mstn gene expression overexpressed in the arterial tunica media, infiltrating cells, and neovas, namely in cells of both muscular and hematopoietic lineage, suggesting that inflammation may upregulate Mstn in different organ systems and settings.

Interestingly, this hypothesis was supported by the evidence that, in the uremic vessels, when compared with donor vascular samples, there was a significant increase of CCL2 expression, which is a potent promoter of monocyte adhesion and consequent inflammation.

In addition, considering that in skeletal muscle of uremic patients inflammation and high IL-6 may activate p-Stat3 to stimulate a pathway from C/EBPδ to Mstn and increase activity of proteasome system, we also decided to study vascular expression of MAFbx/Atrogin-1 and MuRF-1. These molecules are E3 major ubiquitin ligases that control the degradation of both skeletal and cardiac muscle by exerting inhibitory effects on Akt-dependent cardiac hypertrophy.

Our results showed that, in uremic vessels, there was an upregulation of Atrogin-1 and MuRF-1 paralleling the upregulation of Mstn, thus confirming the potential role of UPS activation in the pathogenesis of vascular alterations in ESRD.

Remarkably, similar data were found in experimental studies on rabbit aortic smooth muscle cells, that, when exposed to US, presented increased expression of ubiquitin and ubiquitin-activating enzymes (E1) and an enhanced proteosome activity.

Due to the complexity of vascular biology in uremia, we also evaluated the expression of Klotho and VSMC-specific cytoskeletal proteins, such as α-SMA, vimentin, and Smoothelin, a structural protein that promotes contractile activity and myogenic tone in VSMCs. Then, we observed a significant reduction of the protein expression of these molecules in vascular tissue of ESRD patients, a finding that might be considered a signature of the phenotype change occurring in uremia. Notably, it has to be underlined that for all the molecules we studied, we found a general discrepancy between gene and protein expression. Indeed, while Mstn and CCL2 gene expression upregulated in uremic transplant recipients, their protein expression did not increase.

Conversely, we found that in spite of a nonsignificant difference in gene expression, in recipient vessels, there was a significant lower protein expression of Smoothelin and α-SMA, when compared with donor vessels. So, it seems that it is specifically the protein expression to be impaired in uremia, a result that could be explained, at least in part, by the activation of vascular protein degradation systems, as we observed in our patients.

Interestingly, such discrepancy between gene expression and protein content has already been reported in different experimental settings in uremic conditions. In these cases, the authors suggested that either diminished protein production or increased protein degradation (mediated by an enhanced ubiquitin-dependent activity) might concur to reduce the protein levels, while the increased gene expression could also be interpreted as compensatory.

However, the finding of a not increased Mstn tissue protein expression cannot rule out the potential role of Mstn in inducing vascular alterations in uremic patients, also considering that current evidence suggests that Mstn acts mainly at local level in paracrine or endocrine manner.

Among cytoskeleton proteins, the study of gene and protein expression of vimentin, which we found both downregulated, deserves a special attention. Indeed, vimentin, a component of intermediate filaments, is thought to reflect specific differentiation.
In uremic condition, inflammation and accumulation of uremic toxins can stimulate Mstn and ubiquitin ligase expression and downregulate cytoskeletal proteins and Klotho. Moreover, *in vitro* data indicate that in VSMCs Mstn, *per se*, is a profibrotic trigger and could contribute to vascular remodeling. The possible direct interactions among Mstn, Atrogin-1, MuRF-1, and expression of cytoskeletal proteins and Klotho in uremic vessels are still unknown (dotted circle). Continuous and dotted lines represent positive or negative interactions, respectively.

**Fig. 9.** Putative role of Mstn in uremic vascular biology

In uremic condition, inflammation and accumulation of uremic toxins can stimulate Mstn and ubiquitin ligase expression and downregulate cytoskeletal proteins and Klotho. Moreover, *in vitro* data indicate that in VSMCs Mstn, *per se*, is a profibrotic trigger and could contribute to vascular remodeling. The possible direct interactions among Mstn, Atrogin-1, MuRF-1, and expression of cytoskeletal proteins and Klotho in uremic vessels are still unknown (dotted circle). Continuous and dotted lines represent positive or negative interactions, respectively.
in mineral metabolism, which increase the risk for vascular calcification, may act as a nidus for a local inflammatory response\(^{47}\) seems excluded by the evidence that Mstn vascular expression was not associated with serum phosphate, calcium, or PTH levels in patients studied here. Another possibility is that some circulating molecules are sensed by muscle as danger signal to mount an inflammatory response. A number of uremic retention solutes, such as guanidine compounds, exert pro- and anti-inflammatory effects on monocyte/macrophage function\(^{48}\). In addition, Zhang et al. observed that the upregulation of Mstn in skeletal muscle of patients with CKD is dependent on the pro-inflammatory IL-6/Jak/Stat3 pathway\(^{20}\).

Coherently, our finding that CCL2 gene expression is upregulated in uremic vascular wall confirms that inflammation could have a prominent role in inducing Mstn expression and perpetuating vascular damage in uremic setting.

A limitation in this study is that the control group was made of age-matched, but not comorbidity-free, kidney donors who included hypertensive and active smoker subjects, with low albumin levels. So, it is conceivable that some difference in calcification or fibrosis could have been more evident if healthy subjects had been compared to ESRD patients studied here.

Moreover, because of technical and ethical issues, we compared vascular samples from different sources (aortic artery from donors vs. iliac artery form recipients). Therefore, we cannot rule out that this disparity has impacted on the results, mainly on the study of vascular calcification, even if clinical evidence suggests that there is no difference among the distinctive site of vascular calcification sites in predicting mortality in ESRD patients\(^{40}\).

Anyway, the inclusion of a cohort of nonselected ESRD patients with large dialytic vintage and incident for kidney transplant is one of the strength of the current study, even though it is possible that our cohort may not be indicative of uremia per se but may rather express the combined events occurring in aging and renal disease. In this regard, it is interesting that both cell senescence and Mstn are upregulated in sarcopenia of aging, suggesting that the findings observed in patients studied herein may represent an acceleration of processes “naturally” leading to sarcopenia in elderly subjects.

Finally, enrollment of a small number of patients did not allow a complete analysis of the correlations among vascular alterations, Mstn expression, and patient clinical characteristics.

Nevertheless, despite these weaknesses, our results can help to understand the Mstn as a new player involved in vascular aging and arterial stiffness in CKD patients.

**Conclusions**

In conclusion, we think that the characterization of Mstn in the vascular wall of uremic patients and the study of its potential relationship with cellular and tissue alterations present in this specific setting not only can contribute to improve our knowledge on the pathogenesis of vascular diseases in ESRD but also might also provide new therapeutic targets. This is particularly true for Mstn, that is currently object of many researches, studying the potentiality of its pharmacological inhibition on promoting increased muscle mass and improving metabolic profile and frailty in different disease conditions\(^{50-52}\).

**Conflict of Interest Statement**

None declared.

**Financial Disclosures**

Nothing to declare.

**References**

1) Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis, 2003; 41: 11-17
2) Kooman JP, van der Sande FM, Leunissen KM. Kidney disease and aging: A reciprocal relation. Exp Gerontol, 2017; 87: 156-159
3) Quek KJ, Boyd R, Ameer OZ, Zangerl B, Butlin M, Murphy TV, Avolio AP, Phillips JK. Progressive vascular remodelling, endothelial dysfunction and stiffness in mesenteric resistance arteries in a rodent model of chronic kidney disease. Vascul Pharmacol, 2016; 81: 42-52
4) Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant, 2000; 15: 218-223
5) London GM. Arterial Stiffness in Chronic Kidney Disease and End-Stage Renal Disease. Blood Purif, 2018; 45: 154-158
6) Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circulation research, 2016; 118: 692-702
7) Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Ann Rev Physiol, 2012; 74: 13-40
8) Ackers-Johnson M, Talasila A, Sage AP, Long X, Bot I, Morrell NW, Bennett MR, Miano JM, Sinha S. Myocardin regulates vascular smooth muscle cell inflammatory activation and disease. Arterioscler Thromb Vasc Biol, 2015; 35: 817-828
9) Shanahan CM. Mechanisms of vascular calcification in...
20) Zhang L, Pan J, Dong Y, Teardy DJ, Dong Y, Garibotto G. Apoptosis and myostatin mRNA are upregulated by inducing vascular smooth muscle cell dysfunction and monocYTE recruitment. Sci Rep, 2017; 7: 46362

19) Verszola D, Procopio V, Sofia A, Villaggio B, Villaggio B, Bruniell C, Balbi M, Ameri P, Montecucco F, Palombo D, Ghiglioni G, Garibotto G, Lindeman JH, Barisione C. Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment. Sci Rep, 2017; 7: 46362

18) Verszola D, Milanesi S, Bertolotto M, Garibaldi S, Villaggio B, Brunelli C, Balbi M, Ameri P, Montecucco F, Palombo D, Ghiglioni G, Garibotto G, Lindeman JH, Barisione C. Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocYTE recruitment. Sci Rep, 2017; 7: 46362

20) Zhang L, Pan J, Dong Y, Teardy DJ, Dong Y, Garibotto G, Mitch WE. Stat3 activation links a C/EBPβ to myostatin pathway to stimulate loss of muscle mass. Cell Metab, 2013; 18: 368-379

21) Esposito P, La Porta E, Calatroni M, Grignano MA, Milanesi S, Verszola D, Battaglia Y, Gregorini M, Libetta C, Garibotto G, Rampino T. Modulation of Myostatin/ Hepatocyte Growth Factor Balance by Different Hemodilysis Modalities. Biomed Res Int, 2017; 2017: 7635459

22) Dong J, Dong Y, Chen Z, Mitch WE, Zhang L. The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/adipogenic progenitor cells in chronic kidney disease. Kidney Int, 2017; 91: 119-128

23) Williams MJ, Sugatan T, Agapova OA, Fang Y, Gaut JP, Faugere MC, Malluche HH, Hruska KA. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int, 2018; 93: 147-158

24) Esposito P, Rampino T, Gregorini M, Gabanti E, Bianzina S, Dal Canton A. Mechanisms underlying sCD40 production in hemodialysis patients. Cell Immunol, 2012; 278: 10-15

25) Verszola D, Cappuccino L, D`Amato E, Villaggio B, Gianiorio F, Mij M, Simonato A, Viazz F, Salvidio G, Garibotto G. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int, 2014; 86: 1229-1243

26) Junqueira LCU, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J, 1979; 11: 447-455

27) Churchman AT, Siow RC. Isolation, culture and characterization of vascular smooth muscle cells. Methods Mol Biol, 2009; 467: 127-138

28) Verszola D, Bonann A, Sofia A, Montecucco F, D`Amato E, Cademartori V, Parodi EL, Viazz F, Venturelli C, Brunori G, Garibotto G. Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease. J Cachexia Sarcopenia Muscle, 2017; 8: 131-144

29) Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nature reviews Nephrology, 2014; 10(9): 504-516

30) Song Y, Shen H, Schenten D, Shan P, Lee PJ, Goldstein DR. Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2012; 32: 103-109

31) Silva KA, Dong J, Dong Y, Dong Y, Schor N, Teardy DJ, Zhang L, Mitch WE. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem, 2015; 290: 11177-11187

32) Lecker SH, Jago RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB Journal, 2004; 18: 39-51

33) Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest, 2007; 114: 3211-3223

34) Willis MS, Schisler JC, Li L, Rodriguez JE, Hilliard EC, Charles PC, Patterson C. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circulation Research, 2009; 105: 80-88

35) Zhang YQ, Feng B, Yuan FH. Effect of chronic renal failure on the ubiquitin-proteasome pathway of arterial muscle cells. Mol Med Rep, 2013; 7: 1021-1025

40) Scholze A, Krueger K, Diederich M, Räther C, Scholze A, Pomberger M, Thilo F, Zidek W, Tepel M. Superoxide dismutase type 1 in monocytes of chronic kidney disease patients. Amino Acids, 2011; 41: 427-438

36) Junqueira LCU, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J, 1979; 11: 447-455

27) Churchman AT, Siow RC. Isolation, culture and characterization of vascular smooth muscle cells. Methods Mol Biol, 2009; 467: 127-138

28) Verszola D, Bonann A, Sofia A, Montecucco F, D`Amato E, Cademartori V, Parodi EL, Viazz F, Venturelli C, Brunori G, Garibotto G. Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease. J Cachexia Sarcopenia Muscle, 2017; 8: 131-144

29) Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nature reviews Nephrology, 2014; 10(9): 504-516

30) Song Y, Shen H, Schenten D, Shan P, Lee PJ, Goldstein DR. Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2012; 32: 103-109

31) Silva KA, Dong J, Dong Y, Dong Y, Schor N, Teardy DJ, Zhang L, Mitch WE. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem, 2015; 290: 11177-11187

32) Lecker SH, Jago RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB Journal, 2004; 18: 39-51

33) Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest, 2007; 114: 3211-3223

34) Willis MS, Schisler JC, Li L, Rodriguez JE, Hilliard EC, Charles PC, Patterson C. Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circulation Research, 2009; 105: 80-88

35) Zhang YQ, Feng B, Yuan FH. Effect of chronic renal failure on the ubiquitin-proteasome pathway of arterial muscle cells. Mol Med Rep, 2013; 7: 1021-1025

36) Scholze A, Krueger K, Diederich M, Räther C, Torges A, Scholze A, Pomberger M, Thilo F, Zidek W, Tepel M. Superoxide dismutase type 1 in monocytes of chronic kidney disease patients. Amino Acids, 2011; 41: 427-438

37) Tan R, Zhang J, Tan X, Zhang X, Yang J, Liu Y. Down-regulation of Snon expression in obstructive nephropathy is mediated by an enhanced ubiquitin-dependent degrana-
dation. J Am Soc Nephrol, 2006; 17: 2781-2791
38) Lee, Y. S., Huynh, T. V., Lee, S. J. Paracrine and endo-
ocrine modes of myostatin action. J Appl Physiol (1985),
2016; 120: 592-598
39) Gabbiani G, Schmid E, Winter S, Chaponnier C, de
Ckhastonay C, Vandelkerkhove J, Weber K, Franke WW.
Vascular smooth muscle cells differ from other smooth
muscle cells: Predominance of vimentin filaments and a
specific alpha-type actin. Proc Natl Acad Sci USA, 1981;
78: 298-302
40) Häversen L, Sundelin JP, Mardinoglu A, Rutberg M,
Stählman M, Wilhelmsson U, Hultén LM, Pekny M,
Fogelstrand P, Bentzon JF, Levin M, Borén J. Vimentin
deficiency in macrophages induces increased oxidative
stress and vascular inflammation but attenuates athero-
sclerosis in mice. Sci Rep, 2018; 8(1): 16973
41) Ritter CS, Zhang S, Delmez J, Finch JL, Slatopolsky E.
Differential expression and regulation of Klotho by pari-
calcitol in the kidney, parathyroid, and aorta of uremic
rats. Kidney Int, 2015; 87: 1141-1152
42) Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-
o M, Moe OW. Klotho deficiency causes vascular calcifi-
cation in chronic kidney disease. J Am Soc Nephrol,
2011; 22: 124-136
43) Lim K, Lu TS, Molostrov G, Lee C, Lam FT, Zehnder D,
Hsiao LL. Vascular Klotho deficiency potentiates the
development of human artery calcification and mediates
resistance to fibroblast growth factor 23. Circulation,
2012; 125: 2243-2255
44) Lindberg K, Olauison H, Amin R, Ponnusamy A, Goetz
R, Taylor RF, Mohammadi M, Canfield A, Kublickiene K,
Larsson TE. Arterial klotho expression and FGF23 effects
on vascular calcification and function. PLoS One, 2013;
8: e60658
45) Yamada S, Giachelli CM. Vascular Calcification in CKD-
MBD: Roles for Phosphate, FGF23 and Klotho. Bone,
2017; 100: 87-93
46) Mencke R, Harms G, Mirković K, Struijk J, Van Ark J,
Van Loon E, Verkaik M, De Borst MH, Zeebregts CJ,
Hoenderop JG, Vervloet MG, Hillebrands JL; NIGRAM
Consortium. Membrane-bound Klotho is not expressed
dependently in healthy or uraemic human vascular tis-
tue. Cardiovasc Res, 2015; 108: 220-231
47) Shroff R, Long DA, Shanahan C. Mechanistic insights
into vascular calcification in CKD. J Am Soc Nephrol,
2013; 24: 179-189
48) Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J,
Lameire NH, De Deyn PP, Vanholder RC. In vitro study
of the potential role of guanidines in leukocyte functions
related to atherogenesis and infection. Kidney Int, 2004;
65: 2184-2192
49) Hong D, Wu S, Pu L, Wang F, Wang Z, Gao H,
Zhang Y, Deng F, Li G, He Q, Wang L. Abdominal aortic
calcification is not superior over other vascular calcifica-
tion in predicting mortality in hemodialysis patients: a
retrospective observational study. BMC Nephrol, 2013;
14: 120
50) Han, H. Q., Zhou, X., Mitch, W. E., Goldberg A. L.
Myostatin/activin pathway antagonism: molecular basis
and therapeutic potential. Int J Biochem Cell Biol, 2013;
45: 2333-2347
51) Camporez JP, Petersen MC, Abudukadier A, Moreira GV,
Jurczak MJ, Friedman G, Haqq CM, Petersen KF, Shul-
man GI. Anti-myostatin antibody increases muscle mass
and strength and improves insulin sensitivity in old mice.
Proc Natl Acad Sci USA, 2016; 113: 2212-2217
52) Rentier C, Takayama K, Saitoh M, Nakamura A, Ikeyama
H, Taguchi A, Taniguchi A, Hayashi Y. Design and syn-
thesis of potent myostatin inhibitory cyclic peptides.
Bioorg Med Chem, 2019; 27: 1437-1443